At the last ASCO congress 2021, positive data from a phase II trial of the combination of BRAF and MEK inhibitors (Vemurafenib/cobimetinib) in PCP (Alliance A071601 trial, NCT03224767) have been presented: the objective response was obtained in all but one patient who received at least one cycle of therapy (15/16 patients); median tumor reduction was around 83%. Here, MAP2K7 is linked to neoplasm.